Nanoparticle-Based Mucosal Vaccines Targeting Tumor-Associated Antigens to Human Dendritic Cells

Area of Science:

• Immunology
• Materials Science
• Vaccine Development

Background:

• Effective T cell-mediated immunity is crucial for cancer vaccination.
• Dendritic cells (DCs) are key antigen-presenting cells initiating T cell responses.
• Efficient delivery of tumor antigens to DCs is a major challenge in tumor immunology.

Purpose of the Study:

• To investigate polymeric nanoparticles (chitosan and PLGA-based) for delivering Her2/neu antigen to DCs.
• To assess the potential of these nanoparticles for mucosal vaccination.
• To evaluate the induction of T cell responses by this delivery system.

Main Methods:

• In vitro study using human cells.
• Production of nanoparticles from chitosan and functionalized PLGA polymers.
• Assessment of DC uptake, antigen processing, and presentation.
• Evaluation of T cell proliferation (CD4+ and CD8+) and cytotoxic T cell induction.
• Testing nanoparticle transport across an intestinal epithelium model.

Main Results:

• All tested nanoparticles were efficiently taken up by DCs.
• Nanoparticle-delivered Her2/neu antigen was more effectively processed and presented by DCs compared to soluble protein.
• Nanoparticles induced more vigorous CD4+ and CD8+ T cell proliferation and cytotoxic T cells.
• Nanoparticles efficiently transported across the intestinal epithelium model to reach basolateral DCs.

Conclusions:

• Chitosan and PLGA-based nanoparticles are effective carriers for antigen delivery to DCs.
• These nanoparticles enhance T cell-based immunity induction.
• The nanoparticle platform is suitable for mucosal vaccine formulations.